IL181349A0 - Method of using lanreotide, a somatostatin analogue for preparation of medicaments for treating diseases - Google Patents
Method of using lanreotide, a somatostatin analogue for preparation of medicaments for treating diseasesInfo
- Publication number
- IL181349A0 IL181349A0 IL181349A IL18134907A IL181349A0 IL 181349 A0 IL181349 A0 IL 181349A0 IL 181349 A IL181349 A IL 181349A IL 18134907 A IL18134907 A IL 18134907A IL 181349 A0 IL181349 A0 IL 181349A0
- Authority
- IL
- Israel
- Prior art keywords
- lanreotide
- medicaments
- preparation
- treating diseases
- somatostatin analogue
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9469398P | 1998-07-30 | 1998-07-30 | |
| US12652598A | 1998-07-30 | 1998-07-30 | |
| PCT/US1999/017294 WO2000006185A2 (en) | 1998-07-30 | 1999-07-29 | Methods of using lanreotide, a somatostatin analogue |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL181349A0 true IL181349A0 (en) | 2007-07-04 |
Family
ID=26789150
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14083799A IL140837A0 (en) | 1998-07-30 | 1999-07-29 | Method of using lanreotide, a somatostatin analogue |
| IL181349A IL181349A0 (en) | 1998-07-30 | 2007-02-15 | Method of using lanreotide, a somatostatin analogue for preparation of medicaments for treating diseases |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14083799A IL140837A0 (en) | 1998-07-30 | 1999-07-29 | Method of using lanreotide, a somatostatin analogue |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1100532A2 (en) |
| JP (1) | JP2002521456A (en) |
| KR (1) | KR20010071071A (en) |
| CN (1) | CN1334742A (en) |
| AR (1) | AR023633A1 (en) |
| AU (2) | AU770193B2 (en) |
| BR (1) | BR9912609A (en) |
| CA (1) | CA2335654A1 (en) |
| CZ (1) | CZ2001157A3 (en) |
| HU (1) | HUP0102839A3 (en) |
| IL (2) | IL140837A0 (en) |
| MX (1) | MXPA01000969A (en) |
| NO (1) | NO324123B1 (en) |
| NZ (1) | NZ509348A (en) |
| PL (1) | PL346361A1 (en) |
| WO (1) | WO2000006185A2 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1040837A3 (en) * | 1999-02-26 | 2002-01-02 | Erasmus Universiteit Rotterdam | Medicaments for the treatment of a choroidal neovascularization (CNV) related disorder |
| AU2001283957A1 (en) * | 2000-07-27 | 2002-02-13 | Novartis Ag | Treatment of ocular disorders with somatostatin analogues |
| US6316414B1 (en) | 2000-07-31 | 2001-11-13 | Dabur Research Foundation | Somatostatin analogs for the treatment of cancer |
| ES2345280T3 (en) | 2001-03-06 | 2010-09-20 | The Administrators Of The Tulane Educational Fund | PROCEDURE FOR MODULATION OF THE PROLIFERATION OF MEDULAR THYROID CARCINOMA CELLS. |
| GB0109461D0 (en) * | 2001-04-18 | 2001-06-06 | Univ London | New Gene |
| WO2003061592A2 (en) | 2002-01-22 | 2003-07-31 | New York University | Methods for therapeutic treatment of benign prostatic hypertrophy (bph) |
| CN107446053A (en) | 2008-06-12 | 2017-12-08 | 益普生生物创新有限公司 | The suppression of cancer |
| KR101642363B1 (en) | 2008-06-12 | 2016-07-25 | 입센 바이오이노베이션 리미티드 | Suppression of neuroendocrine diseases |
| GB0820970D0 (en) | 2008-11-17 | 2008-12-24 | Syntaxin Ltd | Suppression of cancer |
| CN101935252B (en) * | 2010-07-29 | 2013-01-30 | 广东省农业科学院科技情报研究所 | Landscape plant growth retardant and preparation method thereof |
| BR112014025058B1 (en) * | 2012-04-12 | 2022-07-12 | Novartis Ag | COMBINATION OF SOMATOSTATIN ANALOGS WITH 11BETA-HYDROXYLASE INHIBITORS, AND THEIR USES |
| CN105168115A (en) * | 2015-09-02 | 2015-12-23 | 中国药科大学 | Oral medication path of somatostatin analogue polypeptide drug |
| WO2017212390A1 (en) * | 2016-06-06 | 2017-12-14 | Emcure Pharmaceuticals Ltd, | Process for lanreotide acetate preparation |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4853371A (en) * | 1986-06-17 | 1989-08-01 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
| US5538739A (en) * | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| ATE140237T1 (en) * | 1989-12-08 | 1996-07-15 | Univ Tulane | OCTAPEPTIDE ANALOGUES OF SOMATOSTATIN WITH THREONINE IN POSITION 6 |
| WO1998008528A1 (en) * | 1996-08-30 | 1998-03-05 | Biomeasure Incorporated | Method of inhibiting fibrosis with a somatostatin agonist |
| WO1998010786A2 (en) * | 1996-09-12 | 1998-03-19 | Yarom Cohen | Pharmaceutical composition for the treatment of syndrome x of reaven |
| DE69822810T2 (en) * | 1997-05-13 | 2005-02-03 | Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. | SOMATOSTATIN AND SOMATOSTATIN AGONIST FOR THE TREATMENT OF INSULIN SENSITIVITY AND SYNDROME X |
-
1999
- 1999-07-29 NZ NZ509348A patent/NZ509348A/en unknown
- 1999-07-29 AU AU52447/99A patent/AU770193B2/en not_active Ceased
- 1999-07-29 CN CN99808953A patent/CN1334742A/en active Pending
- 1999-07-29 WO PCT/US1999/017294 patent/WO2000006185A2/en not_active Application Discontinuation
- 1999-07-29 CA CA002335654A patent/CA2335654A1/en not_active Abandoned
- 1999-07-29 KR KR1020017001277A patent/KR20010071071A/en not_active Application Discontinuation
- 1999-07-29 CZ CZ2001157A patent/CZ2001157A3/en unknown
- 1999-07-29 MX MXPA01000969A patent/MXPA01000969A/en unknown
- 1999-07-29 HU HU0102839A patent/HUP0102839A3/en unknown
- 1999-07-29 BR BR9912609-5A patent/BR9912609A/en not_active IP Right Cessation
- 1999-07-29 PL PL99346361A patent/PL346361A1/en unknown
- 1999-07-29 AR ARP990103765A patent/AR023633A1/en unknown
- 1999-07-29 JP JP2000562039A patent/JP2002521456A/en active Pending
- 1999-07-29 IL IL14083799A patent/IL140837A0/en unknown
- 1999-07-29 EP EP99937658A patent/EP1100532A2/en not_active Withdrawn
-
2001
- 2001-01-29 NO NO20010481A patent/NO324123B1/en not_active IP Right Cessation
-
2004
- 2004-04-29 AU AU2004201783A patent/AU2004201783A1/en not_active Abandoned
-
2007
- 2007-02-15 IL IL181349A patent/IL181349A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CZ2001157A3 (en) | 2002-02-13 |
| PL346361A1 (en) | 2002-02-11 |
| AR023633A1 (en) | 2002-09-04 |
| KR20010071071A (en) | 2001-07-28 |
| HUP0102839A2 (en) | 2002-01-28 |
| MXPA01000969A (en) | 2003-04-07 |
| AU770193B2 (en) | 2004-02-12 |
| NO20010481L (en) | 2001-03-21 |
| WO2000006185A2 (en) | 2000-02-10 |
| HUP0102839A3 (en) | 2002-02-28 |
| CN1334742A (en) | 2002-02-06 |
| BR9912609A (en) | 2001-05-02 |
| JP2002521456A (en) | 2002-07-16 |
| AU2004201783A1 (en) | 2004-05-27 |
| NZ509348A (en) | 2004-02-27 |
| IL140837A0 (en) | 2002-02-10 |
| WO2000006185A3 (en) | 2000-08-03 |
| NO324123B1 (en) | 2007-08-27 |
| AU5244799A (en) | 2000-02-21 |
| NO20010481D0 (en) | 2001-01-29 |
| EP1100532A2 (en) | 2001-05-23 |
| CA2335654A1 (en) | 2000-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL181349A0 (en) | Method of using lanreotide, a somatostatin analogue for preparation of medicaments for treating diseases | |
| HK1086764A1 (en) | A medicine for treating woman climacteric syndromeand preparation method thereof | |
| IL132176A0 (en) | Method for oral delivery of proteins | |
| HUP0100240A3 (en) | A method for maintaining or improving skin health | |
| IL137105A0 (en) | Method for administering aspb28-human insulin | |
| ZA988030B (en) | Fracture healing using pthrp analogs | |
| HUP0004677A3 (en) | A method for improving skin condition | |
| IL128531A0 (en) | Method for treating heart failure | |
| HUP0102902A3 (en) | Cyclic somatostatin analogs, process for production thereof and their use | |
| HUP0000954A3 (en) | Medicinal compositions for treating cardiac diseases caused by cardiac hypertrophy | |
| HUP0102772A3 (en) | Novel compounds derived from alpha-d-xylose, preparation method and therapeutic use | |
| EP0919241A4 (en) | Therapeutic agent, treatment method, prophylactic agent, and prophylactic method for canine and feline immunological diseases | |
| IL125762A0 (en) | Method for treating heart failure | |
| PL332038A1 (en) | Method of treating postmenopausal diseases including osteoporosis | |
| IL140670A0 (en) | Plaster which contains steroids, and a method for production and use thereof | |
| AU2213697A (en) | A method for periodontal disease treatment | |
| TJ264B (en) | A method for treatment of bone cysts of children | |
| EA199900063A3 (en) | Method for treating a patient organism | |
| GB9700841D0 (en) | A method for treating dentures | |
| GB9723534D0 (en) | A method for treating dentures | |
| TJ98000539A (en) | A method of treatment mange | |
| PL330017A1 (en) | Method of obtaining a preparation, in particular in the form of ointment, for treating prophyriate patients | |
| TJ333B (en) | A method for the treatment of virus hepatite | |
| HUP0100584A3 (en) | Triazepinones, process for their preparation and their therapeutic application | |
| AUPP404798A0 (en) | A method of treatment |